Search Result

Results for "

FLT3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (264) AAK1 (2) ADC Antibody (1) Akt (11) AMPK (2) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (1) Apoptosis (113) Aurora Kinase (13) Autophagy (20) Bacterial (1) Bcl-2 Family (1) Bcr-Abl (16) Btk (3) c-Fms (13) c-Kit (44) c-Met/HGFR (12) CaMK (1) Casein Kinase (1) Caspase (3) CDK (17) Checkpoint Kinase (Chk) (4) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (2) Deubiquitinase (1) Discoidin Domain Receptor (4) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (2) Epigenetic Reader Domain (2) ERK (5) Eukaryotic Initiation Factor (eIF) (1) FAK (2) Ferroptosis (7) FGFR (17) Haspin Kinase (2) HDAC (8) HSP (1) IAP (1) IFNAR (2) IKZF Family (1) Insulin Receptor (1) IRAK (11) Isotope-Labeled Compounds (9) JAK (34) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (7) LIM Kinase (LIMK) (2) MAP3K (1) MAP4K (2) MEK (3) MELK (3) Microtubule/Tubulin (1) Mitosis (1) MNK (3) Molecular Glues (1) mTOR (2) MyD88 (6) NF-κB (6) NO Synthase (3) p38 MAPK (3) PAK (1) PDGFR (43) PERK (1) PI3K (4) Pim (2) PKA (1) PKC (4) Polo-like Kinase (PLK) (1) PROTACs (15) RAD51 (3) Raf (7) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (16) RET (14) ROS Kinase (2) Salt-inducible Kinase (SIK) (2) Small Interfering RNA (siRNA) (5) Src (6) STAT (14) STK33 (1) Syk (13) TAM Receptor (13) Target Protein Ligand-Linker Conjugates (2) TGF-beta/Smad (2) TGF-β Receptor (2) Tie (1) Topoisomerase (1) Trk Receptor (9) ULK (1) VEGFR (46) Wee1 (1)
By Research Areas:	Cancer (303) Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (35) Metabolic Disease (1) Neurological Disease (4)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (5)

323

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: FLT3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112475

Flt-3 Inhibitor III	Tie FLT3	Cancer
Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an ₅₀ of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .

HY-168702

FLT3 ligand-2	Ligands for Target Protein for PROTAC	Cancer
FLT3 ligand-2 is a Ligand for Target Protein for PROTAC. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader 1 (HY-114323) .

HY-RS04991

Flt3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt3 Mouse Pre-designed siRNA Set A Flt3 Mouse Pre-designed siRNA Set A

HY-E70724

FLT3 ITD Recombinant Human Active Protein Kinase	FLT3	Cancer
FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 ITD is a internal tandem duplication (ITD) mutation of FLT3 that may be present in AML cells. FLT3 ITD Recombinant Human Active Protein Kinase is a recombinant FLT3 ITD protein that can be used to study FLT3 ITD-related functions .

HY-RS04992

Flt3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Flt3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Flt3 Rat Pre-designed siRNA Set A Flt3 Rat Pre-designed siRNA Set A

HY-RS04990

FLT3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FLT3 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FLT3 Human Pre-designed siRNA Set A FLT3 Human Pre-designed siRNA Set A

HY-170769

FLT3 Ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates FLT3	Cancer
FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the *FLT3* ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases .

HY-E70723

FLT3 D835Y Recombinant Human Active Protein Kinase	FLT3	Cancer
FLT3 (FMS-like tyrosine kinase 3, CD135) is a type 3 receptor tyrosine kinase that plays important roles in cell survival, proliferation, and differentiation during normal hematopoiesis. FLT3 is one of the most frequently mutated genes in acute myeloid leukemia (AML). FLT3 D835Y is the most frequent kinase domain mutation, converting aspartic acid to tyrosine. FLT3 D835Y Recombinant Human Active Protein Kinase is a recombinant FLT3 D835Y protein that can be used to study FLT3 D835Y-related functions .

HY-156410

FLT3-IN-23	FLT3	Cancer
FLT3-IN-23 (compound 15) is an inhibitor of JFMS-like tyrosine kinase 3 (FLT3) with an IC₅₀ of 7.42 nM. FLT3-IN-23 has antiproliferative activities against BaF3 cells carrying various FLT3-TKD and FLT3-ITD-TKD mutations .

HY-178020

FLT3-IN-34	FLT3 ERK Akt Apoptosis	Cancer
FLT3-IN-34 is a *FLT3* inhibitor, with an IC₅₀ value of 1.4 nM. FLT3-IN-34 blocks the phosphorylation of *FLT3* and its downstream signaling molecules AKT and ERK1/2. FLT3-IN-34 induces concentration-dependent G0/G1 phase arrest and mild apoptosis in *FLT3*-ITD-positive MV4-11 cells. FLT3-IN-34 shows potent anti-proliferative activity against FLT3-ITD-positive MV4-11 cells (IC₅₀ = 14.95 nM) and MOLM-13 (IC₅₀ = 18.5 nM). FLT3-IN-34 can be used for the study of *FLT3*-positive acute myeloid leukemia (AML) .

HY-155302

FLT3-IN-22	FLT3	Cancer
FLT3-IN-22 (compound 22f) is a potent *FLT3* inhibitor with IC₅₀ values of 0.941 nM and 0.199 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-22 exhibits strong antiproliferative activity against MV4-11 cells and the mutant FLT kinase expressed Ba/F3 cell lines, including FLT-D835Y and FLT3-F691L .

HY-163068

FLT3-IN-24	FLT3	Cancer
FLT3-IN-24 (compound 24) is a potent and selective inhibitor of FLT3 kinase with an IC₅₀ of 7.94 nM. FLT3-IN-24 has cell antiproliferative effects .

HY-134481

FLT3-IN-10	FLT3	Cancer
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML) .

HY-143895

FLT3-IN-12	FLT3	Cancer
FLT3-IN-12 is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 1.48 nM and 2.87 nM for *FLT3-WT* and *FLT3-D835Y, respectively. FLT3-IN-12* possesses high selectivity over c-KIT (>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11, IC₅₀ of 0.75 nM) .

HY-155226

FLT3-IN-21	FLT3 Apoptosis	Cancer
FLT3-IN-21 (compound LC-3) is a potent FLT3 inhibitor (IC₅₀: 8.4 nM) and induces apoptosis. FLT3-IN-21 can arrest the cell cycle in the G1 phase and inhibit the proliferation of FLT3-ITD-positive AML cells MV-4-11 (IC₅₀: 5.3 nM). In mice, FLT3-IN-21 (10 mg/kg/d) inhibited tumor growth in the MV-4-11 xenograft model (TGI=92.16%) .

HY-148070

FLT3-IN-17	FLT3 FAK Cytochrome P450	Cancer
FLT3-IN-17 inhibits CYPs and *FLT3* mutants activity (IC₅₀s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC₅₀ value of 12 nM. FLT3 ligand-2 can be used in the research of cancers .

HY-161323

FLT3-ITD/D835Y-IN-1	FLT3 Bcr-Abl Apoptosis	Cancer
FLT3-ITD/D835Y-IN-1 (Compound 1) is a *FLT3-ITD* and BCR-ABL inhibitor. FLT3-ITD/D835Y-IN-1 mediates proapoptosis by inhibiting the FLT3 and BCR-ABL pathways, as well as other possible targets. FLT3-ITD/D835Y-IN-1 can be used in the study of acute myeloid leukemia (AML) .

HY-174911

FLT3-IN-33	FLT3 Apoptosis	Cancer
FLT3-IN-33 (Compound 7r) is a *FLT3* inhibitor with an IC₅₀ of 7.82  nM. FLT3-IN-33 has superior anticancer activities against acute myeloid leukemia (AML) cells, such as MV4-11 and MOLM-13 cells. FLT3-IN-33 significantly induces cell apoptosis and inhibits phosphorylation of FLT3 pathways. FLT3-IN-33 can be used for AML and other cancers research .

HY-174437B

FLT3-IN-32 hydrochloride	FLT3 Apoptosis STAT p38 MAPK Akt	Cancer
FLT3-IN-32 hydrochloride is a potent and orally active *FLT3* inhibitor with an IC₅₀s of 0.29 nM, 0.77 nM and 2.07 nM against FLT3-ITD, FLT3-D835Y and FLT-N676K. FLT3-IN-32 hydrochloride reduces the phosphorylation of FLT3 and its downstream signaling molecules (STAT5, MAPK, AKT) to induce FLT3-mutated Ba/F3 cells apoptosis. FLT3-IN-32 hydrochloride shows significant anti-tumor efficacy in n the MV4-11 xenograft model. FLT3-IN-32 hydrochloride can be used for the study of acute myeloid leukemia (AML) .

HY-115904

FLT3/CDK4-IN-1	CDK FLT3	Cancer
FLT3/CDK4-IN-1 is a potent, high selective and orally active *FLT3/CDK4* dual inhibitor (IC₅₀=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .

HY-174437A

FLT3-IN-32 TFA	FLT3	Cancer
FLT3-IN-32 TFA is a potent *FLT3* inhibitor with an IC₅₀s of 2.40 nM and 3.83 nM against FLT3-ITD and FLT3-D835Y. FLT3-IN-32 TFA inhibits proliferation/survival of human MV4-11 cells with an IC₅₀ of 0.07 nM. FLT3-IN-32 TFA can be used for the study of acute myeloid leukemia (AML) .

HY-174137

FLT3-IN-31	Apoptosis FLT3	Cancer
FLT3-IN-31 (compound 10q) is a potent *FLT3* inhibitor with IC₅₀ values of 0.16, 2.4 nM for FLT3, FLT3-D835Y, resprctively. FLT3-IN-31 shows antiproliferation activity. FLT3-IN-31 decreases the protein expression of p-FLT3, P-STAT5, P-ERK. FLT3-IN-31 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-31 shows antitumor activity .

HY-112145

FLT3-IN-3 3 Publications Verification	FLT3	Cancer
FLT3-IN-3 is a potent *FLT3* inhibitor with IC₅₀s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

HY-144777

FLT3-IN-14	FLT3 Apoptosis	Cancer
FLT3-IN-14 is a potent *FLT3* inhibitor with IC₅₀s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model .

HY-162032

FLT3-IN-25	FLT3	Cancer
FLT3-IN-25 (compound 17) is a potent inhibitor of *FLT3, with IC₅₀s of 1.2 nM, 1.4 nM and 1.1 nM for FLT3-WT, FLT3-D835Y* and FLT3-ITD, respectively. FLT3-IN-25 plays an important role in acute myeloid leukemia (AML) .

HY-148522

FLT3-IN-18	FLT3	Cancer
FLT3-IN-18 is a potent and selective *FLT3* inhibitor with an IC₅₀ value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML) .

HY-174437

FLT3-IN-32	FLT3 Apoptosis	Cancer
FLT3-IN-32 is a potent and orally active *FLT3* inhibitor. FLT3-IN-32 shows high selectivity for *FLT3* and efficiently inhibits *FLT3*-activating mutations and induces apoptosis. FLT3-IN-32 shows good tolerability in non-tumor bearing mice. FLT3-IN-32 demonstrates outstanding anti-tumor efficacy in MV4-11 bearing NOD/SCID mice, prolonging the survival noticeably. FLT3-IN-32 can be used for the research of acute myeloid leukemia .

HY-128572

FLT3-IN-6	FLT3	Cancer
FLT3-IN-6 is a potent and selective inhibitor of *FLT3-ITD* (FLT3 mutation) with an IC₅₀ of 1.336 nM .

HY-146886

FLT3-IN-15	FLT3	Cancer
FLT3-IN-15 is a highly potent and orally active *FLT3* inhibitor with IC₅₀s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia .

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3 ^D835Y, *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-155770

FLT3-IN-20	FLT3	Cancer
FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor with IC₅₀ values of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. FLT3-IN-20 has anti-proliferation efficacy in FLT3-ITD-positive AML cell lines MV4-11 and MOLM-13 (7 and 9 nM, respectively) and the MOLM-13 variant (4 nM) with the FLT3-ITD-D835Y mutation. FLT3-IN-20 can be used in research of cancer .

HY-170640

FLT3-IN-29	FLT3 Reactive Oxygen Species (ROS) Apoptosis	Cancer
FLT3-IN-29 (Compound MY-10) is a *FLT3* inhibitor (IC₅₀s: 6.5 and 10.3 nM for FLT3-ITD and FLT3-D835Y mutants). FLT3-IN-29 arrests cell cycle at the G0/G1 phase and efficiently induces Apoptosis. FLT3-IN-29 also reduces reactive oxygen species (ROS) production and mitochondrial membrane potential (MMP). FLT3-IN-29 displays antileukemic activity .

HY-143894

FLT3-IN-11	FLT3	Cancer
FLT3-IN-11 (compound 30) is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 7.22 nM and 4.95 nM for wild-type FLT3 and *FLT3-D835Y, respectively. FLT3-IN-11* high selectivity for FLT3 over c-KIT (>1000-fold). FLT3-IN-11has excellent anti-acute myeloid leukemia (AML) activity (MV4-11 cells, IC₅₀ of 3.2 nM) .

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against *FLT3* and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .

HY-148036

FLT3-IN-16	FLT3	Cancer
FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-153473

FLT3-IN-19	FLT3	Cancer
FLT3-IN-19 (Comp 50) is a potent and selective *FLT3* inhibitor with IC₅₀ of 0.213 nM. FLT3-IN-19 can be used in AML disease research .

HY-148036S

FLT3-IN-16-d1	Isotope-Labeled Compounds FLT3	Cancer
FLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-18744

FLT3-IN-2	FLT3	Cardiovascular Disease Cancer
FLT3-IN-2 (Compound P-0266) is a *FLT3* inhibitor with an IC₅₀ of < 1 μM. FLT3-IN-2 can be used in acute myeloid leukemia research .

HY-160848

FLT3/ITD-IN-5	FLT3	Cancer
FLT3/ITD-IN-5 (Example 6) is an orally active *FLT3* and *FLT3-ITD* inhibitor, with IC₅₀ values of 0.088 and 0.348 nM, respectively. FLT3/ITD-IN-5 can be used for the research of cancer .

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent *FLT3/TrKA* dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML) .

HY-168741

FLT3-ITD-IN-2	FLT3	Cancer
FLT3-ITD-IN-2 (Compound A1) is an inhibitor for FLT3-ITD kinase with an IC₅₀ of 2.12 nM. FLT3-ITD-IN-2 inhibits the proliferation of FLT3-dependent human AML cell line MOLM-13 with an IC₅₀ of 25.65 nM. FLT3-ITD-IN-2 exhibits antitumor efficacy against acute myeloid leukemia .

HY-170576

FLT3-IN-28	FLT3 STAT Apoptosis	Cancer
FLT3-IN-28 (Compound 12y) is an orally active *FLT3* inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the *FLT3* internal tandem duplication (ITD) mutation, with IC₅₀ values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation). Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of *FLT3* and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD .

HY-173214

FLT3-ITD-IN-3	FLT3 Apoptosis	Cancer
FLT3-ITD-IN-3 (13v), an orally active FLT3-ITD (FLT3 internal tandem duplication) inhibitor, disrupts *FLT3* signal transduction and induced G0/G1 cell cycle arrest and apoptosis. FLT3-ITD-IN-3 (13v) is used in the research of acute myeloid leukemia (AML) .

HY-162906

FLT3/HDAC-IN-2	HDAC FLT3	Cancer
FLT3/HDAC-IN-2 is (compound 25h) a *FLT3/HDAC* dual inhibitor. FLT3/HDAC-IN-2 has antiproliferative activity against MOLM-13 cells. FLT3/HDAC-IN-2 can be used in acute myeloid leukemia research .

HY-169076

FLT3/HDAC-IN-1	FLT3 HDAC Apoptosis	Cancer
FLT3/HDAC-IN-1 is a dual inhibitor of *FLT3/HDAC, with IC₅₀* values of 30.4, 52.4, and 14.7 nM for FLT3, HDAC1, and HDAC3, respectively. FLT3/HDAC-IN-1 can induce apoptosis in MV-4-11 cells and has anti-proliferative effects on FLT3 mutant-transformed BaF3 cells. FLT3/HDAC-IN-1 is being researched for its potential in treating hard-to-treat solid tumors and hematological malignancies .

HY-168213

FLT3-IN-27	FLT3	Cancer
FLT3-IN-27 (compound 49) is a *FLT3-ITD* inhibitor with the IC₅₀ of 174 nM. FLT3-IN-27 inhibits cell growth and increases the number of cells in the G1 phase of the cell cycle and can be used for study of acute myeloid leukemia .

HY-143278

FLT3-IN-13	Topoisomerase FLT3 Apoptosis	Cancer
FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and *FLT3* dual inhibitor with IC₅₀ values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia .

HY-146680

FLT3/ITD-IN-4	FLT3 RET CDK MAP4K	Cancer
FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC₅₀ of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research .

HY-162367

FLT3/CHK1-IN-2	FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1-IN-2 (Compound 30) is a dual inhibitor of *FLT3* and CHK1, with IC₅₀s of 25.63, 16.39, 22.80 nM for CHK1, FLT3-WT, and FLT-D835Y respectively. FLT3/CHK1-IN-2 has favorable oral PK properties and kinase selectivity. FLT3/CHK1-IN-2 can be used for research of acute myeloid leukemia (AML) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0071

Crotonoside Isoguanosine	Alkaloids Classification of Application Fields Other Alkaloids Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits *FLT3* and *HDAC3/6*, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-107417

Hypothemycin	Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Phenols Disease Research Disease Research Fields Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, MEK1/MEK2, *FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-N10221

Petromurin C	Alkaloids Monophenols Microorganisms Classification of Application Fields Source classification Phenols Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Petromurin C is a bisindolylbenzenoid compound isolated from the ascostromata of Petromycesmuricatus. Petromurin C induces protective autophagy and apoptosis in FLT3-ITD-positive AML .

Cat. No.	Product Name	Chemical Structure

HY-12432S1

Gilteritinib-d8
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-16379S

Pacritinib-d4
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively ^[3].

HY-10230S

Midostaurin-d5
Midostaurin-d₅ (PKC412-d₅) is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM .

HY-148036S

FLT3-IN-16-d1
FLT3-IN-16-d1 is the deuterium labeled FLT3-IN-16 (HY-148036). FLT3-IN-16 is a potent *FLT3* inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-13001S

Quizartinib-d8

Quizartinib-d₈ (AC220-d₈) is deuterium labeled Quizartinib. Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC₅₀s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-108263S

3-Hydroxy Midostaurin-d5
3-Hydroxy Midostaurin-d₅ is a deuterium labeled 3-Hydroxy Midostaurin. 3-Hydroxy Midostaurin is a metabolite of PKC412, which effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC₅₀s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-W751180

3-Hydroxy Midostaurin-13C6

3-Hydroxy Midostaurin- ¹³C₆ (CGP52421- ¹³C₆) is the ¹³C-labeled 3-Hydroxy Midostaurin (HY-108263). 3-Hydroxy Midostaurin (CGP 52421), a metabolite of PKC412, effectively inhibits FMS-like tyrosine kinase-3 (FLT3) autophosphorylation with IC₅₀s of approximately 132 nM and 9.8 μM in culture medium and plasma, respectively. 3-Hydroxy Midostaurin is less selective but more cytotoxic than PKC412 .

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-10201S4

Sorafenib-d3 tosylate

Sorafenib-d₃ (Donafenib-d₃) tosylate is the deuterium labeled Sorafenib (HY-10201). Sorafenib is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib-d3tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib-d3tosylate induces autophagy and apoptosis. Sorafenib-d3tosylate has anti-tumor activity. Sorafenib is a ferroptosis activator .

HY-W751179

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects ^[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks